We make it simple to start small and scale quickly—with fast pilots, real-world validation, and population-level insights. Our multi-modal AI and enterprise-scale datasets power bespoke solutions for biopharma and diagnostics—seamlessly integrating into existing workflows; no new assays required.
Zephyr helps biopharma teams gain population-level insights and uncover biology driving response. By leveraging the full power of our multi-modal AI and enterprise-scale real-world data, we de-risk trials and accelerate translation.
Fine-tune AI models to your drug and assay for patient stratification, trial optimization, and indication expansion—including novel MOAs
Zephyr’s AI enriches reports with biological interpretability and precision insights, while enabling the co-development of AI-enabled tools for research and clinical development. Our software integrates seamlessly into existing workflows—no new assays required.
Enrich DNA or methylation panels with RUO gene expression–based signatures and precision medicine insights, validated in real-world cohorts to demonstrate performance and clinical utility
Partner with pharma and providers to co-develop tools that inform indication strategy, support label expansion and lifecycle management, drive adoption, and unlock additional value from existing or legacy LDTs
We support pilots, proof-of-concept studies, and full development programs. Whether you’re validating a diagnostic, generating custom cohorts, or powering market access strategies, Zephyr meets you where you are, and scales with you.
